Антибиотики и Химиотерапия

Расширенный поиск

Имипенем: 30 лет терапии

Полный текст:

Об авторах

С. В. Сидоренко
ФГБУ НИИ детских инфекций ФМБА России

И. В. Партина
ФГБУ НИИ детских инфекций ФМБА России

В. А. Агеевец
ФГБУ НИИ детских инфекций ФМБА России

Список литературы

1. Rodloff A.C., Goldstein E.J.C., Torres A. Two decades of imipenem therapy. J of Antim Chem 2006; 58: 916-929.

2. Birnbaum J., Kahan F.M., Kropp H. et al. Carbapenems, a new class of β-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985; 787: 3-21.

3. Kropp H., Gerckens L., Sundelof J.G. et al. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev Infect Dis 1985; 7 Suppl 3: S389-410.

4. Watanabe M., Iyobe S., Inoue M., Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 147-151.

5. Senda K., Arakawa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K., Kato N., Ohta M. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996; 40:3 49-353.

6. Pournaras S., Maniati M., Petinaki E., Tzouvelekis L.S., Tsakris A., Legakis N.J., Maniatis A.N. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-β-lactamase gene variants blaVIM-2 and blaVIM-4. Antimicrob Chemother 2003; 51: 1409-1414.

7. Livermore, D.M., Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000; 3: 489-495.

8. Hota S., Hirji Z., Stockton K. et al. Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design. Inf Control Hosp Epid 2009; 30: 1.

9. Гостев B.B., Сидоренко C.B. SCCmec кассеты, эволюция и генетические линии метициллинорезистентных золотистых стафилококков. Антибиотики и химиотер. 2012; 9-10: 39-46.

10. Mouton J.W., Touw D.J., Horrevorts A.M. et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201.

11. Balfour J., Bryson H., Brogden R. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 99-136.

12. Lavan G., Nord C. Adverse effects of monobactams and carbapenems. Drug Safety 1995; 12: 305-13.

13. Drusano G.L., Craig W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Chemotherapy 1997; 9 Suppl 3: 38-44;

14. Яковлев C.B. Имипенем. Оценка роли препарата при антибактериальной терапии тяжёлых госпитальных инфекций. Антибиотики и химиотер. 1999; 5: 33-37.

15. Novelli A., Adembri C., Livi P. et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44: 539-549.

16. Lee L.S., Bertino J.S. Jr. Comparison of imipenem/cilastatin and meropenem attainment of pharmacodynamic target goals at various dosage regimens using a short infusion time (30 minutes). Clin Pharmacol Therapeut 2004; 75: 14.

17. Kuti J.L., Dandekar P.K., Nightingale C.H. et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-23.

18. Dandekar P.K., Maglio D., Sutherland C.A. et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3 hour infusion. Phamacotherapy 2003; 23: 988-991.

19. Lee L.S., Bertino J.S. Jr. Use of a prolonged infusion time (3 hours) in attaining pharmacodynamic target goals of imipenem-cilastatin and meropenem at various dosing regimens. Clin Pharmacol Therapeut 2004; 75: P15.

20. Mattoes H., Kuti J.L., Drusano G.L. et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26: 1187-1198.

21. Benfield P., Chrisp P. Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intraabdominal infections. PharmacoEconomics 1992; 1: 443-459.

22. Balfour J.A., Bryson H.M., Brogden R.N. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 1: 99-136.

23. Calandra G.B., Wang C., Aziz M. et al. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimib Chemother 1986; 18: Suppl E: 193-202.

24. Pestotnik S., Classen D.C., Evans R.S. et al. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 1993; 27: 497-501.

25. Day I.P., Goudie J., Nishiki K. et al. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin, and meropenem. Toxicol Lett 1995; 76: 239-243.

26. Norrby S.R. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15: 87-90.

27. Basoli A., Zarba E.Z., Mazzocchi P. et al. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997; 29: 503-508.

28. Geroulanos S. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Antimicrob Chemotherapy 1995; 36 Suppl A: 195-205.

29. Koppel B., Hauser W.A., Politis C. et al. Seizures in the critically ill: the role of imipenem. Epilepsia 2004; 42: 1590-1593.

30. Shah P., Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemotherapy 2003; 52: 538-542.

31. Paterson D., Ko W.-C., Von Gottberg A. et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.

32. Vardakas K.Z., Tansarli G.S., Rafailidis P.I., Falagas M.E. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. JAC 2012; 67: 2793-2803.

33. Ibrahim E., Sherman G., Ward S. et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.

34. West M., Boulanger B.R., Fogarty C. et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 2592: 485-506.

35. Cherif H., Bjorkholm M., Engervall P. et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36: 593-600.

36. Erasmo A.A., Crisostomo A.C., Yan L.N. et al. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patiens with intra-abdominal infection. Asian J Surg 2004; 27: 227-235.

37. Kollef M.H. et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care 2012, 16: R218.

38. Kollef M.H., Sherman G., Ward S. et al. Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.

39. Valles J., Rello J., Ochagavia A. et al. Community-acquired bloodstream infection in critically ill adult patients. Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-1624.

40. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A. et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the Intensive Care Unit with sepsis. Crit Care Med 2003; 31: 2742-2751.


Для цитирования:

Сидоренко С.В., Партина И.В., Агеевец В.А. Имипенем: 30 лет терапии. Антибиотики и Химиотерапия. 2013;58(5-6):55-61.

For citation:

Sidorenko S.V., Partina I.V., Ageevets V.A. Imipenem: 30-Year Experience in Therapy. Antibiotics and Chemotherapy. 2013;58(5-6):55-61. (In Russ.)

Просмотров: 177

ISSN 0235-2990 (Print)